448
Views
8
CrossRef citations to date
0
Altmetric
Research Article

Recovery of pigmentation following selective photothermolysis in adult zebrafish skin: clinical implications for laser toning treatment of melasma

, , , , , & show all
Pages 277-285 | Received 19 Jan 2012, Accepted 05 Oct 2012, Published online: 11 Oct 2012

References

  • Chan NP, Ho SG, Shek SY, Yeung CK, Chan HH. A case series of facial depigmentation associated with low fluence Q-switched 1,064 nm Nd:YAG laser for skin rejuvenation and melasma. Lasers Surg Med. 2010;42:712–719.
  • Mun JY, Jeong SY, Kim JH, Han SS, Kim IH. A low fluence Q-switched Nd:YAG laser modifies the 3D structure of melanocyte and ultrastructure of melanosome by subcellular-selective photothermolysis. J Electron Microsc (Tokyo). 2011; 60:11–18.
  • Ho SG, Chan HH. The Asian dermatologic patient: review of common pigmentary disorders and cutaneous diseases. Am J Clin Dermatol. 2009;10:153–168.
  • Cho SB, Kim JS, Kim MJ. Melasma treatment in Korean women using a 1064-nm Q-switched Nd:YAG laser with low pulse energy. Clin Exp Dermatol. 2009;34:e847–850.
  • Polnikorn N. Treatment of refractory dermal melasma with the MedLite C6 Q-switched Nd:YAG laser: two case reports. J Cosmet Laser Ther. 2008;10:167–173.
  • Jeong SY, Chang SE, Bak H, Choi J-H, Kim IH. New melasma treatment by colliminated low fluence Q-switched Nd:YAG laser. Korean J Dermatol. 2008;46:1163–1170.
  • Chung WK, Yang JH, Lee DW, Chang SE, Lee MW, Choi JH, Moon KC. Paradoxical darkening of unperceived tattoo ink after relatively low fluence from a Q-switched Nd:YAG (1064-nm) laser in the course of treatment for melasma. Clin Exp Dermatol. 2009;34:e555–7.
  • Kim MJ, Kim JS, Cho SB. Punctate leucoderma after melasma treatment using 1064-nm Q-switched Nd:YAG laser with low pulse energy. J Eur Acad Dermatol Venereol. 2009;23:960–962.
  • Suh KS, Sung JY, Roh HJ, Jeon YS, Kim YC, Kim ST. Efficacy of the 1064-nm Q-switched Nd:YAG laser in melasma. J Dermatolog Treat. 2011;22:233–8.
  • Wattanakrai P, Mornchan R, Eimpunth S. Low-fluence Q-switched neodymium-doped yttrium aluminum garnet (1,064 nm) laser for the treatment of facial melasma in Asians. Dermatol Surg. 2010;36:76–87.
  • Jeong SY, Shin JB, Yeo UC, Kim WS, Kim IH. Low-fluence Q-switched neodymium-doped yttrium aluminum garnet laser for melasma with pre- or post-treatment triple combination cream. Dermatol Surg. 2010;36:909–918.
  • Draelos ZD. Commentary: low-Fluence Q-Switched neodymium-doped yttrium aluminum garnet laser for melasma with pre- or post-treatment triple combination cream. Dermatol Surg. 2011;37:126–7.
  • Kim JH, Kim H, Park HC, Kim IH. Subcellular selective photothermolysis of melanosomes in adult zebrafish skin following 1064-nm Q-switched Nd:YAG laser irradiation. J Invest Dermatol. 2010;130:2333–2335.
  • Hirata M, Nakamura K, Kondo S. Pigment cell distributions in different tissues of the zebrafish, with special reference to the striped pigment pattern. Dev Dyn. 2005;234: 293–300.
  • Hirata M, Nakamura K, Kanemaru T, Shibata Y, Kondo S. Pigment cell organization in the hypodermis of zebrafish. Dev Dyn. 2003;227:497–503.
  • Logan DW, Burn SF, Jackson IJ. Regulation of pigmentation in zebrafish melanophores. Pigment Cell Res. 2006;19:206–213.
  • Richardson J, Lundegaard PR, Reynolds NL, Dorin JR, Porteous DJ, Jackson IJ, Patton EE. mc1r Pathway regulation of zebrafish melanosome dispersion. Zebrafish. 2008;5: 289–295.
  • Elsalini OA, Rohr KB. Phenylthiourea disrupts thyroid function in developing zebrafish. Dev Genes Evol. 2003;212: 593–598.
  • Karlsson J, von Hofsten J, Olsson PE. Generating transparent zebrafish: a refined method to improve detection of gene expression during embryonic development. Mar Biotechnol (NY). 2001;3:522–527.
  • White RM, Zon LI. Melanocytes in development, regeneration, and cancer. Cell Stem Cell. 2008;3:242–252.
  • Ando H, Itoh A, Mishima Y, Ichihashi M. Correlation between the number of melanosomes, tyrosinase mRNA levels, and tyrosinase activity in cultured murine melanoma cells in response to various melanogenesis regulatory agents. J Cell Physiol. 1995;163:608–614.
  • Ni-Komatsu L, Leung JK, Williams D, Min J, Khersonsky SM, Chang YT, Orlow SJ. Triazine-based tyrosinase inhibitors identified by chemical genetic screening. Pigment Cell Res. 2005;18:447–453.
  • Chawla S, deLong MA, Visscher MO, Wickett RR, Manga P, Boissy RE. Mechanism of tyrosinase inhibition by deoxyArbutin and its second-generation derivatives. Br J Dermatol. 2008;159:1267–1274.
  • Choi TY, Kim JH, Ko DH, Kim CH, Hwang JS, Ahn S, . Zebrafish as a new model for phenotype-based screening of melanogenic regulatory compounds. Pigment Cell Res. 2007;20:120–127.
  • Yang CT, Sengelmann RD, Johnson SL. Larval melanocyte regeneration following laser ablation in zebrafish. J Invest Dermatol. 2004;123:924–929.
  • Kim JH, Baek SH, Kim DH, Choi TY, Yoon TJ, Hwang JS, . Downregulation of melanin synthesis by haginin A and its application to in vivo lightening model. J Invest Dermatol. 2008;128:1227–1235.
  • Love DR, Pichler FB, Dodd A, Copp BR, Greenwood DR. Technology for high-throughput screens: the present and future using zebrafish. Curr Opin Biotechnol. 2004;15: 564–571.
  • Ceol CJ, Houvras Y, White RM, Zon LI. Melanoma biology and the promise of zebrafish. Zebrafish. 2008;5:247–255.
  • Hill AJ, Teraoka H, Heideman W, Peterson RE. Zebrafish as a model vertebrate for investigating chemical toxicity. Toxicol Sci. 2005;86:6–19.
  • Bresch H, Beck H, Ehlermann D, Schlaszus H, Urbanek M. A long-term toxicity test comprising reproduction and growth of zebrafish with 4-chloroaniline. Arch Environ Contam Toxicol. 1990;19:419–427.
  • Langheinrich U. Zebrafish: a new model on the pharmaceutical catwalk. Bioessays. 2003;25:904–912.
  • Hatamoto K, Shingyoji C. Cyclical training enhances the melanophore responses of zebrafish to background colours. Pigment Cell Melanoma Res. 2008;21:397–406.
  • Westerfield M. The zebrafish book. A guide for the laboratory use of zebrafish (Danio rerio). Eugene, Oregon: University of Oregon Press; 2000.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.